HemaCare is the leading global provider of human-derived cellular material, supplying controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood, bone marrow, and cord blood. HemaCare supports biotechnology and pharmaceutical companies, academic institutions, and research organization who rely on high-quality, viable, and functional human primary cells and blood components for biomedical and drug discovery research and cell therapy development.
Corporate Reports and Filings
News and Events
HemaCare and Charles River Laboratories Partner to Provide Human-Derived Biological Material to ChinaHemaCare and Charles River Laboratories partner to provide human-derived biological material to ChinaREAD MORE
HemaCare Reports First Half 2019 ResultsHemaCare reports on operational highlights and financial results for the six months ended June 30, 2019READ MORE
HemaCare will be exhibiting at the CAR-TCR Summit 2019. Be sure to stop by our booth (#60) to learn more about how HemaCare can support the development of the next generation of CAR-TCR therapies with our GMP-compliant products and services.READ MORE
Investor Relations Contact Information
(877) 310-0717 (option 8)
250 Royall Street
Canton, MA 02021
The statements contained in this website which are not historical facts are forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control, with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
HemaCare voluntarily delisted from NASDAQ in 2012 due to the significant costs of remaining a public company and is no longer required to be registered with the SEC. HemaCare is currently traded on the OTCMKTS (Pink Sheets) under “HEMA”.
Note: It is the policy of HemaCare not to respond to email inquiries via return email. If you have a specific question regarding HemaCare, please call.